Our Mission
To improve the lives of patients affected by transthyretin amyloidoses through innovative therapeutic approaches.
Oculopathy
CNS Angiopathy
Polyneuropathy
Cardiomyopathy
Our News
What is happening in our universe.
BSIM Therapeutics was present at the 11th International Conference on Chemical Structures (Noordwijkerhout, The Netherlands) on May 27-31
BSIM Therapeutics was present at the XVIth International Symposium on Amyloidosis (Kumamoto, Japan) on March 26-29
“Uma startup de Coimbra quer entrar para a história das ciências portuguesas como a primeira empresa portuguesa a desenvolver um medicamento tendo como ponto de partida simulações de computador."
BSIM Therapeutics has recently secured a €1 million grant to target one lead compound to the CNS and to the eye and conclude lead optimization.
By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more
